Table 5.
Efficacy Results of Nivolumab as Second-Line Treatment of Metastatic Non-Squamous NSCLC (non-small cell lung cancer).
| Efficacy | Nivolumab (n = 292) | Docetaxel (n = 290) |
|---|---|---|
| Overall Survival | ||
| Deaths (%) | 190 (65%) | 223 (77%) |
| Median (months) (95% CI) | 12.2 (9.7, 15.0) | 9.4 (8.0, 10.7) |
| p-Value a,b | 0.0015 | |
| Hazard ratio (95% CI) c | 0.73 (0.60, 0.89) | |
| Objective Response Rate | 56 (19%) | 36 (12%) |
| (95% CI) | (15, 24) | (9, 17) |
| p-Value d | 0.02 | |
| Complete response | 4 (1.4%) | 1 (0.3%) |
| Partial response | 52 (18%) | 35 (12%) |
| Median Duration of response (months) | 17 | 6 |
| Progression-Free Survival | ||
| Disease progression or death (%) | 234 (80%) | 245 (84%) |
| Median (months) | 2.3 | 4.2 |
| p-Value a | 0.39 | |
| Hazard ratio (95% CI) c | 0.92 (0.77, 1.11) | |
a Based on stratified log-rank test; b p-value is compared with .0408 of the allocated alpha for this interim analysis; c Based on a stratified proportional hazards model; d Based on the stratified Cochran-Mantel-Haenszel test.